retatrutide type 2 diabetes phase 2 trial results The data just dropped β and is rewriting what's possible in obesity medicine. 𧬠TRIUMPH-1 just released 3 results, and the numbers are unlike anything we've seen from a medication: Lilly's triple agonist delivers up
Description
The Trump Administration is delivering big news in Medicare
Advice on treatment or care of an individual patient should be obtained through consultation with a trained health care practitioner
commercial health claims data covering over 50 million insured individuals - including 139,000 GLP-1 users from 2022 to 2024 - our findings reveal powerful insights: Cost Savings:In their second year, GLP-1 users showed a 7% improvement in the growth of medical spend - a strong indicator of potential long-term savings for employers
Thinking about GLP-1 injections for weight loss
3ml / 10ml / 30ml
